title: Paradoxical growth hormone response following thyroid-stimulating hormone administration in the polycystic ovary syndrome.
abstract: Growth hormone (GH) and prolactin (PRL) responses after TRH administration were studied in 31 women presenting with the clinical, biochemical and ultrasonographic characteristics of the polycystic ovarian (PCO) syndrome; their results were compared with those of 20 normally menstruating women investigated during the early follicular phase of the cycle. Based on the GH responses two PCO subgroups were observed: (a) nonresponders (n = 16) who showed delta max GH responses (0.7 +/- 0.27 ng/ml, x +/- SE) similar to those of the normals (0.97 +/- 0.20 ng/ml), and (b) responders (n = 15), 48.4% of the PCO patients who showed a paradoxical increase in GH levels (delta max GH, 18.0 +/- 1.96 ng/ml) following thyrotropin-releasing hormone (TRH) administration significantly higher than those observed either in nonresponder PCO patients or in normals. Furthermore, basal GH levels were found to be significantly higher in the responder PCO subgroup (5.65 +/- 0.75 ng/ml) compared to either nonresponders (1.58 +/- 0.21 ng/ml) or normals (1.8 +/- 0.18 ng/ml). However, no correlation was found between basal GH levels and delta max GH responses observed. Additionally, basal PRL and delta max PRL levels following TRH administration did not differ either between the two PCO subgroups or those observed in normal controls. delta 4A, T and E2 levels were similar between the two PCO subgroups. No correlation was found between the delta max GH responses to delta max PRL or the post-luteinizing hormone-releasing hormone stimulation test delta max luteinizing hormone:follicle-stimulating hormone ratio observed or to steroid levels.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pathologic Physiology, General Laikon Hospital, Medical School, University of Athens, Greece.
authors.forename: M L
authors.initials: ML
authors.lastname: Anapliotou
authors.forename: K
authors.initials: K
authors.lastname: Syrigos
authors.forename: G
authors.initials: G
authors.lastname: Panayiotakopoulos
authors.forename: A
authors.initials: A
authors.lastname: Kalos
authors.forename: M L
authors.initials: ML
authors.lastname: Batrinos
mesh_terms: D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013006:Growth Hormone